Values of Ga-DOTATOC and Carbidopa-assisted F-DOPA PET/CT for insulinoma localization.
Fiche publication
Date publication
juillet 2021
Journal
Journal of nuclear medicine : official publication, Society of Nuclear Medicine
Auteurs
Membres identifiés du Cancéropôle Est :
Pr IMPERIALE Alessio
Tous les auteurs :
Imperiale A, Boursier C, Sahakian N, Ouvrard E, Chevalier E, Sebag F, Addeo P, Taïeb D
Lien Pubmed
Résumé
To assess the value of Ga-DOTATOC and carbidopa-assisted F-DOPA in 21 hypoglycaemic patients. All patients who underwent Ga-DOTATOC and/or carbidopa-assisted F-DOPA PET/CT for suspicion of insulinoma from January 2019 to January 2021 were retrospectively analysed. Insulinoma final diagnosis was defined according to pathological reports or consensus. During the study period, 21 patients underwent both Ga-DOTATOC and F-DOPA PET/CT. A final diagnosis of insulin-secreting tumour was reached in 12 cases, including 11 insulinomas and 1 small mixed neuroendocrine/non-neuroendocrine neoplasm. F-DOPA and Ga-DOTATOC PET/CT were positive in 5 (45%) and 7 (64%) of 11 cases, respectively, with 4 concordant positive findings. Moreover, 1 insulinoma was visualized exclusively by F-DOPA PET/CT and 3 by Ga-DOTATOC PET/CT only. F-DOPA and Ga-DOTATOC PET/CT were falsely positive in 1 non-functioning pancreatic neuroendocrine tumour. When Ga-exendin-4 is not available, Ga-SSTR PET/CT should be the first choice for insulinoma functional imaging.
Mots clés
18F-DOPA, 68Ga-DOTATOC, Endocrine, Neuroendocrine, PET/CT, insulinoma, neuroendocrine tumors, pancreas
Référence
J Nucl Med. 2021 Jul 16;: